APstem Therapeutics is pioneering a novel cell therapy technology centered around a unique class of stem cells known as Adult High Plasticity Stem Cells (AHPSCs). These stem cells are derived from human donor blood and are characterized by their exceptional regenerative capabilities and safety profile, which notably includes the absence of tumor formation. The high immunocompatibility of AHPSCs allows for their use in allogeneic clinical applications, making them a versatile option for treating a variety of serious diseases. This innovative approach aims to overcome significant challenges faced by existing stem cell therapies, such as safety concerns and manufacturing complexities.

The advantages of AHPSCs extend beyond their regenerative potential; they also promise a low-cost and efficient manufacturing process sourced from healthy donors. This positions APstem Therapeutics to address critical barriers in the field of regenerative medicine, offering a safer and more accessible alternative for patients in need of advanced therapeutic options. The company's commitment to leveraging the healing power of human blood through AHPSCs underscores its potential to transform treatment paradigms for a wide range of diseases.

United States

With APstem Therapeutics’ breakthrough discovery of Adult Pluripotent Stem Cells (APSCs™), we are on a mission to eradicate difficult-to-heal diseases and conquer the challenges of aging.

Age-related diseases

Cancer

Cardiovascular Diseases

Endocrine System Diseases

Liver Diseases

Lung Diseases

Skin Diseases

APstem Therapeutics

Diabetic foot ulcer

AP-Skin-01 (AHPSCs™)

Biologics

Cell Therapies

California - North

California

Regenerative Medicine

Stem Cells

Therapeutic

APstem Therapeutics

Company Details